Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis

Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.

Automated summary

Invasive fungal diseases (IFD) continue to be a major cause of morbidity and mortality, necessitating the development of new treatment approaches. Recent data suggest that checkpoint inhibitors (ICI) may have a beneficial effect. This report presents a case of a diabetic patient with refractory IFD following SARSCoV-2 infection, who was treated with ICI and interferon-gamma in combination with antifungal therapy.